Time to Diversify Out of Semiconductors
If you need proof that the price action in the semiconductor sector is worse than the action in the overall market, look no further than the Philad...
Bristol Myers Squibb Co (BMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Pzena Investment Management Richard S. Pzena | 14,244,839 | $888,877,954 | -17% | 2.61% |
| 2. | Leucadia National Ian Cumming And Joseph Steinberg | 418,780 | $26,131,872 | -18% | 0.19% |
| 3. | Fisher Asset Management Ken Fisher | 213,131 | $13,299,429 | +23% | 0% |
| 4. | Motley Fool Asset Management Bryan Hinmon | 176,699 | $11,026,018 | +1% | 0.42% |
| 5. | Skylands Capital Charles Paquelet | 131,000 | $8,174,400 | -6% | 1.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $47.58 | 4,250 | $202,215.00 | 83,513 | 2025-04-25 | Filing | |
| $55.05 | 2,000 | $110,096.00 | 104,626 | 2025-02-20 | Filing | |
| $54.84 | 1,823 | $99,999.97 | 63,932 | 2025-02-14 | Filing | |
| $54.68 | 1,830 | $100,055.25 | 62,109 | 2024-11-01 | Filing | |
| $49.78 | 2,000 | $99,560.00 | 82,672 | 2023-12-05 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $63.31 | 3,800 | $240,578.00 | 30,279 | 2026-11-05 | Filing | |
| $64.57 | 6,249 | $403,497.93 | 18,748 | 2026-09-09 | Filing | |
| $67.50 | 500 | $33,750.00 | 16,862 | 2026-08-25 | Filing | |
| $62.05 | 4,481 | $278,046.05 | 159,248 | 2026-04-01 | Filing | |
| $61.60 | 25,519 | $1,571,970.40 | 163,729 | 2026-04-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 50,641,973 | $3,151,221,305 | 0.16% | |
| 2. | 20,045,596 | $1,251,033,824 | 0.23% | |
| 3. | 19,850,731 | $1,238,685,583 | 0.2% | |
| 4. | 10,776,120 | $672,429,886 | 0.19% | |
| 5. | 9,674,145 | $603,671,012 | 0.12% |
News See All
Options Volatility and Implied Earnings Moves This Week, October 26 – October 30, 2026
This week, several major companies will be reporting earnings. Among them are Amazon (AMZN), Microsoft (MSFT), Alphabet Class A (GOOGL), Alphabet C...
11 Best Cancer Stocks to Invest In Now
Cancer’s Burden Keeps the Search for Better Treatments Urgent For cancer patients, progress means more time, fewer side effects, and a better chance of recovery.
Bristol Myers (BMY) Has New Cancer Wins. Can They Offset the Patent Cliff?
Positive Oncology Data Meets an Older-Drug Problem Bristol-Myers Squibb Company (NYSE:BMY) reported positive data from its radiopharmaceutical RYZ101 Phase III ACTION-1 trial and additional progress across...
Bristol Myers vs. Eli Lilly: Is BMY’s Deep Valuation Discount Hiding an Opportunity?
Bristol-Myers Squibb Company (NYSE:BMY) and Eli Lilly and Company (NYSE:LLY) are almost opposites in the pharmaceutical market.
Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a Catch
Bristol-Myers Squibb Company (NYSE:BMY) looks cheaper than Pfizer Inc. (NYSE:PFE) on earnings, even though its latest revenue growth was stronger.
Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
Over the last year, Bristol-Myers Squibb Company (NYSE:BMY) has done better than the overall market, with its shares increasing by nearly 40% as a result of new medicines contributing to revenue growth...
Bristol Myers (BMY) Stock is Trading Below 10 Times Forward Earnings. Here’s Why it Matters
Bristol-Myers Squibb Company (NYSE:BMY) is in an interesting spot. The company is still one of the biggest names in pharmaceuticals, but its investment story is changing.
AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing.